title: Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma.
abstract: Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC), although it is known to cause a variety of dermatologic adverse events. Subcorneal pustular dermatosis (SCPD), also known as Sneddon-Wilkinson disease, is a rare skin eruption that accompanies various systemic disorders and may become chronically progressive. We herein describe the case of a patient who developed SCPD after sorafenib administration. The dermatologic reaction was improved by the cessation of sorafenib and worsened by its readministration. Clinicians treating HCC patients with sorafenib should be aware of the possibility of SCPD.
authors: The Third Department of Internal Medicine, Toyama University Hospital, Japan.
authors: Kazuto
authors: K
authors: Tajiri
authors: Takahiko
authors: T
authors: Nakajima
authors: Kengo
authors: K
authors: Kawai
authors: Masami
authors: M
authors: Minemura
authors: Toshiro
authors: T
authors: Sugiyama
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced* / Q000473:pathology; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib